Smallpox vaccination: a review, part II. Adverse events.
about
Frequency of adverse events after vaccination with different vaccinia strainsSmallpox vaccines for biodefense: need and feasibilitySingle-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitorA 33-year-old man with a facial rashCytokine production associated with smallpox vaccine responsesAdverse events post smallpox-vaccination: insights from tail scarification infection in mice with Vaccinia virusPotent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 ProteinOrthopox Viruses: Infections in HumansGenome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipientsEstimating the Size of the U.S. Population at Risk of Severe Adverse Events from Replicating Smallpox Vaccine.Extracting key information from historical data to quantify the transmission dynamics of smallpoxA protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.New class of orthopoxvirus antiviral drugs that block viral maturation.Diversity in the acute CD8 T cell response to vaccinia virus in humans.Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus.The immunology of smallpox vaccines.Gender effects on humoral immune responses to smallpox vaccine.A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.Genomic expression libraries for the identification of cross-reactive orthopoxvirus antigens.Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.A quantitative rabbit model of vaccinia keratitis.Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.Genome-wide genetic associations with IFNγ response to smallpox vaccineThe identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulinImpact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections.Capturing the natural diversity of the human antibody response against vaccinia virusVaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.Smallpox vaccine safety is dependent on T cells and not B cellsEvaluation of therapeutic interventions for vaccinia virus keratitisSmallpox vaccines: targets of protective immunity.IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.
P2860
Q21092385-2C29AB60-4E65-4E25-A78A-549B3B0FA17CQ22305942-C28FDDAE-D3B6-4927-847F-7B22DC7CB663Q24656105-413FA346-2DB5-4973-AB12-BFC135231AB0Q24796579-93ECA929-601F-4017-AB32-361F89FCBC10Q26823501-3A315B1C-3018-460F-8AEB-648E38721D4BQ27346800-D74F4EBB-247D-4141-911E-2F40648400C3Q27684713-C755B926-5C96-499A-AAF6-60E86966E1B4Q28742218-8A7E0882-A157-4C4A-8AE3-31D2939AEC20Q28943252-8137670D-94FD-42C1-86C3-F482BCA6196CQ30151714-41BC9B04-7BA6-4095-8B84-7E0EC79F69D5Q30228781-C5CC41A8-973C-42EB-965D-DEEFF7708D55Q30445071-4C68C7AC-B274-452B-B6F8-CC98863AF87FQ33208347-11CA3722-22F7-4F8C-BC10-1FDFD78EF5A1Q33227607-6349B669-89C6-4BFF-B27A-CC44B7EAD510Q33373339-F4772BB9-FFD9-4134-93D9-E08ECF4C8C77Q33679943-AD0CD661-6403-4A57-AB1D-80A214A9D876Q33701473-784B2012-9ABF-4776-ACC3-48E09FEF738BQ33770909-054C634A-86A9-4CD8-8F2D-91BEA900BF92Q33838507-550C1BEE-F829-4C87-BB98-5CE85731908EQ33936717-47CEAD0A-75BA-4938-ACB4-F4BB7FA8BB90Q33967713-EF6C5CEF-D232-4B20-A12B-102BC07CB3C3Q33968161-3F89F3D7-FB59-4692-B912-239607A9645AQ33987410-82D7F4E5-DBF2-4A31-9463-AC41C6476D53Q33987538-BEBDA1F9-A4B5-4923-AB93-7D7C0643C5E2Q34135490-8700B20D-4185-478A-B8DA-B76161AFA357Q34140816-0CF315F4-CDDB-46CF-93B8-D7C1C7DC4915Q34221936-B2380F7E-DAC3-4D9D-B737-0EC0E52DF4B5Q34288498-5869AABD-DD5B-42C4-AC3F-0E884019FD8FQ34447009-8182F628-49D5-4825-BF93-54B6E5B7E8FCQ34469836-E2314C94-0BD8-4C8C-9220-028567ECC86AQ34478724-ADE98F0D-B2CA-435B-A7E7-55F612C1B6B8Q34484027-1F10483F-0B93-47FE-8304-1CEBFF716373Q34502253-3E280E46-73BE-4DFD-86F9-517D3B5AE6D4Q34510424-1BF812F9-9985-42CA-9FF3-57422D25C5D9Q34529713-C8A2857F-0E5B-41A9-952A-FF2C61EBE96DQ34714569-F9B3DA7B-2FE0-4705-9D17-F2656FE11E7CQ34743303-2C5A047D-501F-49D9-9912-D8E334E52C5BQ34772694-61F2EB82-86C1-460D-A90E-3F9EFB71D34BQ34780607-62ED3ED7-FB6D-4FB5-A970-456766721DE7Q34907430-4BFEC7CF-6D44-44BB-A5E4-8C2EFE4E8493
P2860
Smallpox vaccination: a review, part II. Adverse events.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Smallpox vaccination: a review, part II. Adverse events.
@ast
Smallpox vaccination: a review, part II. Adverse events.
@en
type
label
Smallpox vaccination: a review, part II. Adverse events.
@ast
Smallpox vaccination: a review, part II. Adverse events.
@en
prefLabel
Smallpox vaccination: a review, part II. Adverse events.
@ast
Smallpox vaccination: a review, part II. Adverse events.
@en
P2093
P356
P1476
Smallpox vaccination: a review, part II. Adverse events.
@en
P2093
Arthur Papier
D A Henderson
J Michael Lane
John M Neff
Vincent A Fulginiti
P304
P356
10.1086/375825
P407
P577
2003-07-10T00:00:00Z